Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Genomics Market Outlook 2026-2035 - Featuring Profiles of Illumina, Thermo Fisher Scientific, and Qiagen

globenewswire.com
ILMN Illumina is listed as a key company operating in the global genomics market, which is projected for significant growth. The article does not provide specific positive or negative news about Illumina itself, but places it within a growing industry. TMO Thermo Fisher Scientific is identified as a key player in the expanding genomics market. The article highlights the overall market growth and technological advancements, but does not offer specific sentiment towards Thermo Fisher Scientific. QGEN QIAGEN is mentioned as a key company in the genomics market, which is experiencing substantial growth. The article focuses on industry trends and forecasts, without detailing specific performance or outlook for QIAGEN. NVDA NVIDIA is listed as a key company in the genomics market. The article mentions the integration of AI and advanced data analytics, which aligns with NVIDIA's business, but provides no specific sentiment or performance details for the company. AMGN Amgen is mentioned as a key company in the genomics market. The article highlights the growth of the genomics sector and its application in drug discovery and development, but does not provide specific sentiment towards Amgen. DHR Danaher is listed as a key company operating in the global genomics market. The article discusses the overall market growth and technological advancements but does not offer specific sentiment or performance details for Danaher. DGX Quest Diagnostics is mentioned as a key company in the genomics market. The article focuses on the overall market growth and adoption of genomic technologies in diagnostics, but provides no specific sentiment towards Quest Diagnostics. AGNC Agilent Technologies is listed as a key company in the genomics market. The article discusses the industry's growth and technological advancements but does not provide specific sentiment or performance details for Agilent Technologies. BIIB Biogen is mentioned as a key company in the genomics market. The article highlights the growth of the genomics sector and its application in drug discovery and development, but does not provide specific sentiment towards Biogen. MYGN Myriad Genetics is listed as a key company in the genomics market. The article discusses the overall market growth and adoption of genomic technologies in diagnostics, but provides no specific sentiment towards Myriad Genetics. PACB Pacific Biosciences of California is listed as a key company in the genomics market. The article discusses the industry's growth and technological advancements but does not provide specific sentiment or performance details for Pacific Biosciences of California. BIO Bio-Rad Laboratories is mentioned as a key company in the genomics market. The article highlights the growth of the genomics sector and its application in diagnostics and research, but does not provide specific sentiment towards Bio-Rad Laboratories.

Genomics Market Outlook 2026-2035 - Featuring Profiles of Illumina, Thermo Fisher Scientific, and Qiagen Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

Global Genomics Market Forecast to Reach USD 188.7 Billion by 2035, Driven by Precision Healthcare and Sequencing Innovation

The global genomics market was valued at USD 44.7 billion in 2025 and is projected to reach USD 188.7 billion by 2035, expanding at a compound annual growth rate (CAGR) of 15.6% during the forecast period.

Market growth is being fueled by the increasing prevalence of chronic and inherited disorders, rising demand for precision healthcare, and wider adoption of genomic technologies in clinical diagnostics, pharmaceutical research, therapeutic development, and preventive care. Continued advances in sequencing systems, gene analysis platforms, artificial intelligence, automation, and bioinformatics are improving the speed, accuracy, and scalability of genomic applications across healthcare and life sciences.

Healthcare providers and researchers are increasingly using genomic technologies for disease identification, treatment selection, therapy optimization, and targeted medicine. At the same time, biotechnology and pharmaceutical companies are expanding their genomic research capabilities to accelerate drug discovery and support the development of personalized therapies. Favorable regulatory initiatives, improving reimbursement frameworks, and growing investment in biomedical research are expected to encourage broader adoption across clinical laboratories, research institutions, and healthcare systems.

Genomics Products Segment Maintains Market Leadership

The products segment accounted for 66.9% of the global genomics market in 2025 and is forecast to reach USD 122.7 billion by 2035, registering a CAGR of 15.3% from 2026 to 2035. The segment includes genomic instruments and consumables used in research, testing, and clinical diagnostic workflows.

Technological improvements in genomic equipment are increasing analytical accuracy, operational efficiency, and laboratory throughput. Consumables remain a major source of recurring demand because they are required throughout testing and research processes. The expansion of large-scale genomic studies, clinical testing programs, and precision medicine initiatives is expected to support sustained demand for advanced instruments, reagents, assays, and related laboratory materials.

Sequencing Technologies Generate USD 17 Billion in 2025

The sequencing segment generated USD 17 billion in revenue in 2025. Innovation in sequencing platforms continues to improve processing speed, precision, throughput, and cost efficiency, enabling broader implementation across research and clinical settings. These capabilities are supporting comprehensive genomic analysis, disease-focused research, biomarker discovery, and the development of targeted treatment strategies.

Demand for efficient genomic interpretation is also encouraging the integration of sequencing platforms with artificial intelligence and advanced data analytics. As sequencing workflows become more automated and accessible, their role in diagnostics, biomedical research, and pharmaceutical development is expected to expand further.

North America Holds 42.7% of the Global Genomics Market

North America captured a 42.7% market share in 2025, supported by advanced healthcare infrastructure, substantial biomedical research investment, and early adoption of genomic technologies. Expanding biotechnology activity, precision healthcare initiatives, and strong institutional research networks continue to reinforce the region's leadership.

Rising demand for personalized treatment, early disease detection, and advanced diagnostics is accelerating genomics adoption across the United States and other North American markets. The presence of major industry innovators, combined with continued progress in sequencing, diagnostics, artificial intelligence, and bioinformatics, is also strengthening regional market development.

Competitive Landscape and Strategic Priorities

Key companies operating in the global genomics market include Agilent Technologies, BGI Genomics, Bio-Rad Laboratories, Color Genomics, Danaher, Eppendorf, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Myriad Genetics, NVIDIA, Oxford Nanopore Technologies, Pacific Biosciences of California, QIAGEN, Quest Diagnostics, and Thermo Fisher Scientific.

Leading market participants are investing in research and development to introduce advanced sequencing systems, analytical software, automated workflows, and efficient genomic testing solutions. Strategic partnerships with biotechnology companies, pharmaceutical manufacturers, healthcare providers, and research organizations are helping accelerate innovation and extend genomic applications.

Companies are also using acquisitions and collaborations to broaden product portfolios, strengthen technical capabilities, and expand their international presence. Investment in artificial intelligence, data analytics, laboratory networks, and automation is expected to improve genomic data interpretation, streamline operations, increase accessibility, and support long-term customer relationships.

Comprehensive Global Genomics Market Analysis Includes:

Key Attributes:

Key Topics Covered:

Chapter 1 Methodology and Scope

1.1 Market scope and definition

1.2 Research approach

1.3 Quality commitments

1.3.1 GMI AI policy and data integrity commitment

1.3.1.1 Source consistency protocol

1.4 Research trail and confidence scoring

1.4.1 Research trail components

1.4.2 Scoring components

1.5 Data collection

1.5.1 Partial list of primary sources

1.6 Data mining sources

1.6.1 Paid sources

1.6.1.1 Sources, by region

1.7 Base estimates and calculations

1.7.1 Revenue share analysis

1.7.2 Base year calculation

1.8 Forecast model

1.9 Research transparency addendum

1.9.1 Source attribution framework

1.9.2 Quality assurance metrics

1.9.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360-degreesynopsis

2.2 Key market trends

2.2.1 Regional trends

2.2.2 Type trends

2.2.3 Technology trends

2.2.4 Application trends

2.2.5 End use trends

2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising prevalence of genetic and chronic diseases

3.2.1.2 Advancements in DNA sequencing and gene editing technologies

3.2.1.3 Increasing adoption of precision medicine

3.2.1.4 Government initiatives and funding for genomics research

3.2.2 Industry pitfalls and challenges

3.2.2.1 Ethical and privacy concerns around genetic data

3.2.2.2 High cost and affordability issues

3.2.3 Market opportunities

3.2.3.1 Development of affordable and rapid sequencing technologies

3.2.3.2 Integration of AI and machine learning for enhanced genomic data analysis

3.3 Growth potential analysis

3.4 Technology landscape

3.4.1 Current technology

3.4.2 Emerging technologies

3.5 Pricing Analysis (Driven by Primary Research)

3.6 Regulatory landscape (Driven by primary research)

3.6.1 North America

3.6.2 Europe

3.6.3 Asia-Pacific

3.6.4 Latin America

3.6.5 Middle East and Africa

3.7 Porter's analysis

3.8 PESTEL analysis

3.9 Impact of AI and generative AI on the market

3.10 Future market trends (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

4.1 Introduction

4.2 Company market share analysis

4.2.1 Global

4.2.2 North America

4.2.3 Europe

4.3 Company matrix analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Key developments

4.6.1 Merger and acquisition

4.6.2 Partnership and collaboration

4.6.3 New product launches

4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, by Type, 2022-2035 ($ Mn)

5.1 Key trends

5.2 Products

5.2.1 Instruments

5.2.2 Consumables and reagents

5.3 Services

5.3.1 NGS-based services

5.3.2 Core genomics services

5.3.3 Biomarker translation services

5.3.4 Computational services

5.3.5 Other services

Chapter 6 Market Estimates and Forecast, by Technology, 2022-2035 ($ Mn)

6.1 Key trends

6.2 PCR (polymerase chain reaction)

6.3 Sequencing

6.4 Microarray

6.5 Nucleic acid extraction and purification

6.6 Other technologies

Chapter 7 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)

7.1 Key trends

7.2 Diagnostics

7.3 Drug discovery and development

7.4 Precision medicine

7.5 Agriculture and animal research

7.6 Other applications

Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)

8.1 Key trends

8.2 Hospitals and clinics

8.3 Research centers and academic and government institutes

8.4 Pharmaceutical and biotechnology companies

8.5 Other end users

Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Spain

9.3.5 Italy

9.3.6 Netherlands

9.4 Asia-Pacific

9.4.1 China

9.4.2 India

9.4.3 Japan

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

Chapter 10 Company Profiles

10.1 Agilent Technologies

10.2 BGI Genomics

10.3 Bio-Rad Laboratories

10.4 Color Genomics

10.5 Danaher

10.6 Eppendorf

10.7 Eurofins Scientific

10.8 F. Hoffmann-La Roche

10.9 Illumina

10.10 Myriad Genetics

10.11 NVIDIA

10.12 Oxford Nanopore Technologies

10.13 Pacific Biosciences of California

10.14 QIAGEN

10.15 Quest Diagnostics

10.16 Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/r/jkftdk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.